10.1002/ejoc.201701356
European Journal of Organic Chemistry
FULL PAPER
123.7, 120.2, 115.2, 112.7, 111.3, 96.3, 55.6, 50.3, 43.6, 23.4; IR (KBr) υ:
3204, 2962, 1766, 1699, 1609, 1542, 1438, 1328, 1317,1229, 1174, 1083,
1036, 995, 877, 748, 701 cm-1; MS (m/z): HRMS (ESI) Calcd For
C27H20ClN3O4 ([M+Na]+): 508.1040. Found: 508.1026.
We are grateful to the National Natural Science Foundation of
China (No. 21572196) and the Priority Academic Program
Development of Jiangsu Higher Education Institutions for financial
support (No. BK2013016). The Analytical Center of Yangzhou
University is acknowledged for the analyticalassistance.
General procedure for the synthesis of 7: 1-methyl-3-(phenylamino)-
1H-pyrrole-2,5-dione (1 mmol), acenaphthequinone (1 mmol) and acetic
acid (2 mL) were introduced in a 10 mL initiator reaction vial. Subsequently,
the reaction vial was capped and then pre-stirring for 20 second. The
mixture was irradiated (Time: 20 min, Temperature: 150 oC; Absorption
Level: High; Fixed Hold Time) until TLC (petroleum ether: ethyl acetate
4:1) revealed that conversion of the starting material 1 was completed. The
reaction mixture was then cooled to room temperature and then diluted
with cold water (25 mL). The solid product was collected by Büchner
filtration and was washed with 95% EtOH to give almost pure 7. The solid
was further purified by flash column chromatography (silica gel, mixtures
of ethyl acetate / n-hexane, 4:1, v/v) for its NMR and HRMS analysis.
Keywords: domino annulation reaction• spiro[dihydropyridine-
oxindoles]• cyclization• microwave irradiation• chemoselectivity
[1] (a) M. H. Chen, P. P. Pollard, A. A. Patchett, K. Cheng, L. Wei, W. W. S.
Chan, B. Butler, T. M. Jacks and R. G. Smith, Bioorg. Med. Chem. Lett.,
1999, 9, 1261; (b) M. L. Yao, M. Z. Deng, J. Org. Chem., 2000, 65, 5034;
(c) P. Kongsaeree, S. Prabpai, N. Sriubolmas, C, Vongvein, S. Wiyakrutta,
J. Nat. Prod., 2003, 66, 709; (c) R. Pradhan, M. Patra, A. K. Behera, B. K.
Mishra, R. K. Behera, Tetrahedron., 2006, 62, 779; (d) S. Fantacci, F. D.
Angelis, M. K. Nazeeruddin, M. J. Grätzel, Phys. Chem., C 2011, 115,
23126.
2'-methyl-2H-spiro[acenaphthylene-1,9'-pyrrolo[3,4-b]quinoline]-
1',2,3'(2'H,4'H)-trione(7a). Yellow solid, 68%, m.p. >300 oC; 1H NMR (400
MHz, DMSO-d6) δ: 10.91 (s, 1H, NH), 8.36 (d, J = 8.0 Hz, 1H, ArH), 8.07
(d, J = 7.2 Hz, 1H, ArH), 7.99 (d, J = 8.0 Hz, 1H, ArH), 7.91 (t, J = 8.0 Hz,
1H, ArH), 7.65 (t, J = 7.6 Hz, 1H, ArH), 7.36 (d, J = 6.8 Hz, 1H, ArH), 7.16
(t, J = 7.6 Hz, 1H, ArH), 6.74 (t, J = 7.6 Hz, 1H, ArH), 6.09 (d, J = 7.6 Hz,
1H, ArH), 2.72 (s, 3H, CH3); 13C NMR (100 MHz, DMSO-d6) δ: 203.7, 165.4,
145.0, 142.3, 141.6, 136.5, 132.7, 132.5, 131.6, 130.2, 129.9, 129.4, 129.0,
128.9, 128.8, 128.4, 125.2, 124.8, 124.4, 123.7, 122.1, 121.6, 118.7, 100.6,
54.9, 23.3; IR(KBr) υ: 3248, 2917, 1764, 1707, 1663, 1527, 1468, 1359,
1207, 1032, 969, 804, 758 cm-1; MS (m/z): HRMS (ESI) Calcd For
C23H14N2O3 ([M+H]+): 367.1083. Found: 367.1098.
[2] For selected reviews of spirooxindoline, see: (a) H.Lin and S. J, Angew.
Chem., Int. Ed. 2003, 42, 36; (b) C. V.Galliford, and K. A, Scheidt. Angew.
Chem., Int. Ed. 2007, 46, 8748; (c) F. Zhou, Y. L. Liu and J. Zhou, Adv.
Synth. Catal., 2010, 352, 1381; (d) N. R. Ball-Jones, J. J. Badillo and A. K.
Franz, Org. Biomol. Chem.,2012, 10, 5165; (e) G. S. Singh and Z. Y. Desta,
Chem. Rev., 2012, 112, 6104; (f) L. Hong and R. Wang, Adv. Synth. Catal.,
2013, 355, 1023; (g) M. M. M, Santos Tetrahedron, 2014, 70, 9735; (h) B.
Yu, D. Q. Yu and H. M Liu, Eur. J. Med. Chem., 2015, 97, 673; (i) N. Ye, H.
Chen, E. A. Wold, P. Y. Shi and J. Zhou, ACS Infect. Dis., 2016, 2, 382.
[3] (a) Y. Kia, H. Osman, R. S. Kumar, V. Murugaiyah, A. Basiri, S. Perumal, H.
A. Wahab and C. S. Bing, Bioorg. Med. Chem., 2013, 21, 1696.
[4] (a)Y. Arun, G. Bhaskar, C. Balachandran, S. Ignacimuthu and P. Perumal,
Bioorg. Med. Chem. Lett.,2013, 23, 1839.
2. General procedure for the synthesis of 9: 5,5-dimethyl-3-
(phenylamino)cyclohex-2-en-1-one (1 mmol), indoline-2,3-dione (1 mmol)
acetic anhydride (1 mL) and dioxane (1 mL) were introduced in a 10 mL
initiator reaction vial. Subsequently, the reaction vial was capped and then
pre-stirring for 20 second. The mixture was irradiated (Time: 20 min,
Temperature: 150 oC; Absorption Level: High; Fixed Hold Time) until TLC
(petroleum ether: ethyl acetate 4:1) revealed that conversion of the starting
material 2 was completed. The reaction mixture was then cooled to room
temperature and then diluted with cold water (25 mL). The solid product
was collected by Büchner filtration and was washed with 95% EtOH to give
almost pure 9. The solid was further purified by flash column
chromatography (silica gel, mixtures of ethyl acetate / n-hexane, 4:1, v/v)
for its NMR and HRMS analysis.
[5] (a) J. Qu, L. Fang, X. D. Ren, Y. Liu, S. S. Yu, L. Li, X. Q. Bao, D. Zhang, Y.
Li and S. G. Ma, J. Nat. Prod., 2013, 76, 2203.
[6] (a) K. Rad-Moghadam, L. Youseftabar-Miri, Synlett.,2010, 1969.
[7] (a) K. Ding, Y. P. Lu, Z. Nikolovska-Coleska, G.-P. Wang, S. Qiu, S.
Shangary, W. Gao, D. G. Qin, J. Stuckey, K. Krajewski, P. P. Rolle and S.-
M. Wang, J. Med. Chem., 2006, 49, 3432; (b) P. Prasanna, K. Balamurugan,
S. Perumal, P. Yogeeswari and D. Sriram, Eur. J. Med. Chem., 2010, 45,
5653.
[8] J. P. Wan and Y. Liu, RSC Adv. 2012, 2, 9763.
[8] For some examples in the field of pharmacologicallyproperties of 1, 4-
dihydropyridazines, see: (a) G. M. Reddy, M. Shiradkar and A. K.
Chakravarthy, Curr. Org. Chem.,2007, 11, 847; (b) E. Carosati, P. Ioan, M.
Micucci, F. Broccatelli, G. Cruciani, B. S. Zhoror, A. Chiarini and R. Budriesi,
Curr. Med. Chem., 2012, 19, 4306; (c) J. P. Wan, Y. Liu, RSC Adv., 2012,
2, 9763; (d) S. A. Khedkar and P. B. Auti, Mini-Rev. Med. Chem., 2014, 14,
282–290, and references cited therein.
1'-benzyl-5'-chloro-7-methoxy-3,3-dimethyl-3,4-dihydro-2H-
spiro[acridine-9,3'-indoline]-1,2'(10H)-dione(9a). White solid, 76%, m.p.
>300 oC; 1H NMR (400 MHz, DMSO-d6) δ: 9.76 (s, 1H, NH), 7.54 (d, J =
7.2 Hz, 2H, ArH), 7.35 (t, J = 7.6 Hz, 2H, ArH), 7.28 (t, J = 7.2 Hz, 1H, ArH),
7.17-7.14 (m, 1H, ArH), 6.98-6.96 (m, 1H, ArH), 6.85 (d, J = 7.2 Hz, 1H,
ArH), 6.83-6.82 (m, 1H, ArH), 6.81-6.79 (m, 1H, ArH), 5.92-5.91 (m, 1H,
ArH), 5.01-4.91 (m, 2H, CH2), 3.43 (s, 3H, OCH3), 2.52-2.51 (m, 2H, 2CH),
2.14-2.00 (m, 2H, 2CH), 1.06 (s, 3H, CH3), 1.03 (s, 3H, CH3); 13C NMR
(100 MHz, DMSO-d6) δ: 192.3, 179.2, 153.4, 141.4, 141.1, 137.1, 133.1,
132.7, 129.3, 128.9, 128.1, 127.8, 127.4, 126.7, 126.5, 123.0, 122.9, 116.6,
110.4, 103.8, 51.1, 50.4, 43.6, 41.0, 32.6, 28.6, 27.6, 20.7; IR(KBr)υ: 3066,
3111, 1695, 1595, 1496, 1345, 1169, 1032, 948, 881, 746 cm-1; MS (m/z):
HRMS (ESI) Calcd For C30H27ClN2O3 ([M+H]+): 498.1788. Found:
498.1801.
[9] (a) A. Radadiya, V. Khedkar, A. Bavishi, H. Vala, S. Thakrar, D. Bhavsar,
A. Shah and E. Coutinho, Eur. J. Med. Chem., 2014, 74, 375; (b) Y. J. Ren,
Z. C. Wang, X. Zhang, H. Y. Qiu, P. F. Wang, H. B. Gong, A. Q. Jiang
and H. L. Zhu, RSC Adv., 2015, 5, 21445; (c) Z. Cui, X. Li, L. Li, B. Zhang,
C. Gao, Y. Chen, C. Tan, H. Liu, W. Xie, T. Yang and Y. Jiang, Bioorg.
Med. Chem., 2016, 24, 261.
[10] (a) M. Dabiri, Z. N. Tisseh, M. Nobahar and A. Bazgir, Helv. Chim. Acta.,
2011, 94, 824; (b) J. Quiroga, S. Portillo, A. Pérez, J. Gálvez, R. Abonia
and B. Insuasty Tetrahedron Lett. 2011, 52, 2664; (c) A. Kundu, S. Pathak,
and A. Pramanik, Asian J. Org. Chem. 2013, 2, 869; (d) V. O. Iaroshenko,
S. Dudkin, V. Y. Sosnovskikh, A. Villinger and P. Langer, Synthesis 2013,
971; (e) H. Hosseinjani-Pirdehi, K. Rad-Moghadam and L. Youseftabar-Miri,
Tetrahedron, 2014, 70 1780; (f) A. Rahmati and M. Eskandari-Vashareh, J.
Chem. Sci. 2014, 126, 169.
[11] (a) J. Sun, Y. Sun, H. Gao, C. G. Yan, Eur.J. Org. Chem. 2012, 1976; (b)
Y. Sun, J. Sun, C. G. Yan, Beilstein J. Org. Chem., 2013, 9, 8.
Acknowledgements
This article is protected by copyright. All rights reserved.